OWC Pharmaceutical to Discuss Cannabis-based Therapies at Monaco Event

OWC Pharmaceutical to Discuss Cannabis-based Therapies at Monaco Event
OWC Pharmaceutical Research will give a presentation in Monaco next week on cannabis-based therapies, which studies have shown help people with fibromyalgia, psoriasis and other inflammatory conditions. Yehuda Baruch, the company's chief science officer, will talk about "Cannabis And The Endocannabinoid System: A New And Emerging Pipeline For Medical Products," at the Monaco Growth Forums Spring Edition, April 25-26. A key aim is to create interest in cannabis-based therapies in Europe, the company acknowledged. Cannabis-based treatments have been gaining momentum as a valuable option across a growing range of diseases, including fibromyalgia, psoriasis, multiple myeloma, and migraine headaches. OWC is working on appropriate doses and delivery systems for medical cannabis. Cannabidiol, the plant’s pure molecular compound, has anti-inflammatory and pain-relieving properties, and no known psycho-active effects. Research has shown that cannabidiol can be an effective treatment for many types of pain, particularly inflammatory pain. Among those who benefit from cannabis pain relief are fibromyalgia patients, studies have shown. One testament to the treatment was 
Subscribe or to access all post and page content.